Delivering leading treatment for people with thoracic and gastrointestinal cancers.
Stephen is a widely respected Australasian leader in medical oncology, specialising in thoracic and gastrointestinal cancers, including neuroendocrine cancers and mesothelioma. He also has a special clinical interest in cancer pharmacology and cancer-associated inflammation.
Stephen is an empathic clinician with over 30 years clinical experience in Australia which came after completion of a PhD at the Royal Marsden Hospital in the UK, the largest cancer centre in Europe.
Stephen has been a Professor of Medicine at the University of Sydney since 2004 and from 2014-2020 was Director of Cancer Services in Northern Sydney Local Health District. Stephen has supervised 13 PhD completions of young Medical Oncologists, scientists, and dietitians.
Stephen previously worked at Westmead and Nepean Hospitals (1994-95) and Concord and Royal Prince Alfred Hospitals (1995-2010), and then returned to the North Shore Campus in 2010 to help further enhance and investigate their Australian leading cancer survival advantages.
As a patient in Stephen’s care, you can be sure you’re being cared for by a leading medical oncologist working as part of a dedicated multidisciplinary team.
- Stephen’s contributions to medicine have been recognised with several prestigious awards. In 2011, he was awarded the Order of Australia (OAM) for services to medicine in the disciplines of oncology and pharmacology. In 2016 he was awarded the Medical Oncology Group of Australia Cancer Achievement Award.
- Stephen is committed to educating junior clinicians and cancer scientists. In 2020, he was awarded the John Sands Medal, the highest award of the Royal Australasian College of Physicians for his work in supporting the education and development of young Medical Oncologists and physicians in general.
- In addition to his clinical work, Stephen is a dedicated patient advocate and researcher. He's an oncology advisor for the Department of Veterans' Affairs, and a member of the Repatriation Pharmaceutical Review Committee. His research has been supported by over $28 million dollars in competitive funding which has produced publications that have been cited more than 24,000 times.
- Stephen’s clinical and research interests have included all the issues that are important to cancer patient well-being including new treatments, nutrition, complementary therapies, including medicinal cannabis and exercise.